

European CNS Summit 2016

12th - 14th
September, 2016
London, UK

Targeting Neurodegenerative Diseases

What's the one breakthrough you want to see in the neurodegenerative field over the next 5 years?



“ We live in exciting times when technical developments are enabling us to ask novel questions. Thus, during the next 5 years, I expect not only to witness some successes in ongoing trials, but also the identification and confirmation of a next generation of targets that will then enable the design future clinical trials ”

Professor & Director, Department of Neurodegeneration & Neurorestoration, **University Medical Center Göttingen**

“ Delineating the genuine etiological factor responsible for Alzheimer's pathology ”

Frédéric Checler, Research Director, **INSERM**



“ The successful introduction of precision medicine in neuroscience drug development with subsequent identification of genetic and molecular drivers of pathophysiology and tailored targeted drugs to treat biologically stratified sets of patients with great efficacy and tolerability ”

Harald Hampel, Professor & AXA Research Fund & UPMC Chair, **Sorbonne Universities, Pierre and Marie Curie University**

“ Firstly, the development of pharmacological and life style means to slow aging. Secondly, personalized treatments based on the patients genetic background and possibly life history. I think that, like in cancer, these changes will be gradual as not like infective diseases such as polio and AIDs where the breakthrough was associated with a quantal leap ”

Daniel Michaelson, Professor of Neurobiology, **Tel Aviv University**



“ The development of new end points within AD ”

Birgitte Søgaard, Divisional Director, Clinical & Quantitative Pharmacology, **Lundbeck**

“ Approval of an efficient disease modifying treatment in AD. From a biomarker perspective I also look forward to a valid blood based biomarker within AD so that diagnosis and disease progression is more applicable in the real life setting ”

Helle Sickmann, Clinical Pharmacology Scientist, **Lundbeck**



“ Approval of the first disease modifying treatment for AD ”

Cyrille Sur, Executive Director & Neuroscience Imaging Lead, **Merck**

“ The creation of a platform open to anyone to share the collection of biomarkers in longitudinal studies in healthy and prodromal patients and open source software platforms for the analysis of clinical, neuropsychological, EEG, MRI, and PET data ”

Claudio Babiloni, Associate Professor of Physiology, **University of Rome "La Sapienza"**



“ An understanding of the causal and temporal relationship between Tau and Amyloid pathology, and the impact of intervention on neuronal integrity ”

Garry Honey, Head of Biomarkers & Clinical Imaging, **Roche**

Join the conversation at the **European CNS Summit** to challenge traditional thinking around the development of effective treatments against neurodegeneration.